• drapreau en
  • drapreau fr

  • Programme and abstracts
  • Detailed programme & abstracts

    Keynote lectures
    With the support of Région Occitanie Pyréenées / Méditerrannée
    14:00 - 15:00 - Charting mechanisms of tumor progression and therapeutic resistance
    Douglas HANAHAN, Swiss Institute for Experimental Cancer Research (ISREC), Lausanne, Switzerland
    15:00 - 16:00 - Hypoxia, Metabolism, and Tumor Progression
    M. Celeste SIMON, Abramson Family Cancer Research Institute, UPenn, Philadelphia, PA, United States
    16:00 - 17:00 - Multiple Myeloma: From (almost) no treatment to cure. The past 20 years story
    Hervé AVET-LOISEAU, Cancer Research Center of Toulouse (CRCT), France,
    Session 1 :  Can we really improve DNA damaging agents efficacy ?
    00:00 - 00:00 - Dual processing of R-loops and topoisomerase I induces transcription-dependent DNA double-strand breaks
    Olivier SORDET, Cancer Research Center of Toulouse (CRCT), France
    09:00 - 09:40 - Precision Medicine with DNA-targeted agents
    Yves POMMIER, Developmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, MD, United States
    09:55 - 10:10 - The histone variant macroH2A1.1 inhibits cellular migration by activating paused gene transcription in triple negative breast cancer cells.
    Ludmila RECOULES, CBI, France
    10:10 - 11:00 - Coffee break - Poster session
    11:00 - 11:15 - Telomere and nuclear envelope interaction to drive and maintain 3D genome organization
    Laure CRABBE, Center for Integrative Biology (CBI), Toulouse, France
    11:15 - 11:30 - Chromosome folding controls the response to DNA Double Strand Breaks and translocations
    Coline ARNOULD, Center for Integrative Biology (CBI), Toulouse, France
    11:30 - 12:10 - From DNA repair mechanisms to drug discovery
    Sébastien BRITTON, Institute of Pharmacology and Structural Biology (IPBS), Toulouse, France
    Session 2 :  Targeted therapies and resistance mechanisms
    14:15 - 14:55 - Genomic profiling of metastatic breast cancer
    Fabrice ANDRÉ, Gustave Roussy, Villejuif, France
    14:55 - 15:10 - Preventing acquired resistance to therapy by targeting tumor evolution: a new strategy to prolong lung cancer response to EGFR inhibition
    Luca GRUMOLATO, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
    15:10 - 15:50 - Targeting PI3K isoforms in pancreatic cancer: novel concepts of cooperation / competition in signalling nodes.
    Julie GUILLERMET-GUIBERT, Cancer Research Center of Toulouse (CRCT), France
    15:50 - 16:20 - Coffee break - Poster session
    16:20 - 16:35 - Aryl hydrocarbon Receptor transcription factor promotes “phenotype switching” during acquisition of BRAFi-resistance of melanoma.
    Sébastien CORRE, Institute Genetics & Development of Rennes (IGDR), France
    16:35 - 16:50 - Targeting cancer stem cells to overcome BRAF mutated tumor resistance in CRC
    Julie PANNEQUIN, Institute of Functional Genomics (IGF), Montpellier, France
    16:50 - 17:30 - Nongenetic mechanisms of tumor evolution and therapy resistance
    Jean-Christophe MARINE, VIB KU Leuven Center For Cancer Biology, Belgium
    Session 3 :  Translating oncoimmunology science into survival - With institutional support of MSD
    09:00 - 09:40 - Immunotherapy Approaches in Hematological Malignancies: Pushing the Envelope Towards a Cure
    Nikhil C. MUNSHI, Dana Farber Institute, Medical Oncology, Boston, MA, United States
    09:40 - 09:55 - Tumor antigen-specific CD8 T cells identified by TIM-3 expression predict response to PD-1 blockade in head and neck cancer
    Camille-Charlotte BALANÇA, Cancer Research Center of Toulouse (CRCT), France
    09:55 - 10:35 - New insights from the multimodal profiling of human tumors at the single cell level
    Jean-Jacques FOURNIE, Cancer Research Center of Toulouse (CRCT), France
    10:35 - 11:05 - Coffee break - Poster session
    11:05 - 11:20 - High endothelial venules mediate lymphocyte entry to tumor after CTLA-4 and PD-1 immune checkpoint therapy
    Juliette COUDERT, Institute of Pharmacology and Structural Biology (IPBS), Toulouse, France
    11:20 - 11:35 - Polyclonal anti-tumor cell globulins induce target cell apoptosis and synergize with checkpoint blockade immunotherapy to eradicate hepatocellular carcinoma.
    Bernard VANHOVE, Xenothera, Nantes, France
    11:35 - 11:50 - Neutral sphingomyelinase 2 promotes anti-melanoma immune responses and synergizes with immune checkpoint inhibitors.
    Anne MONTFORT, Cancer Research Center of Toulouse (CRCT), France
    11:50 - 12:05 - Protective role of localized Ca2+ entry into melanoma cells upon rapid CTL lytic granule secretion
    Liza FILALI, Cancer Research Center of Toulouse (CRCT), France
    12:05 - 12:20 - LungPredict: Transcriptomics and imaging to explore the lung cancer tumor microenvironment landscape, a multidisciplinary approach to personalized medicine
    Vera PANCALDI, Cancer Research Center of Toulouse (CRCT), France
    Session 4 : Metabolic vulnerabilities–driven therapies 
    14:15 - 14:55 - Therapeutic Targeting of Metabolic Dependencies in AML
    Marina KONOPLEVA, MD Anderson Cancer Center, Houston, TX, United States
    14:55 - 15:10 - Mitochondrial respiratory complex I supports resistance to venetoclax plus cytarabine in acute myeloid leukemia
    Claudie BOSC, Cancer Research Center of Toulouse (CRCT), France
    15:10 - 15:50 - Mitochondria and Cancer
    Christian FREZZA, MRC Cancer Unit, University Of Cambridge, United Kingdom
    15:50 - 16:20 - Coffee break - Poster session
    16:20 - 16:35 - Autophagy And Lysosomal Regulation is Key for Granulocytic Differentiation of Acute Myeloid Leukemia Cells
    Magali HUMBERT, University of Bern, Switzerland
    16:35 - 16:50 - Capture at the single cell level of metabolic modules distinguishing aggressive and indolent glioblastoma cells
    Elias EL-HABR, Institut de Biologie Paris-Seine (IBPS), France
    16:50 - 17:30 - Roles of the p53 pathway in metabolism: implications in aging, tissue homeostasis and carcinogenesis
    Laurent LE CAM, Institut de Recherche en Cancérologie de Montpellier (IRCM), France
    Organisation des territoires et recensement des structures
    • Loi santé et organisation territoriale
    • Etat des lieux des dispositifs de coordination ville hôpital en Occitanie
    • Retours d’expériences de coordination ville hôpital en cancérologie
    Comment le réseau peut accompagner les territoires pour favoriser la coordination ville hôpital pour les patients atteints de cancer ?

    Quels outils existent pour faciliter la coordination ville hôpital des patients atteints de cancer en Occitanie


    Non-Canonical Functions of Hexokinase 3 During Myeloid Differentiation
    Kristina SEILER, Scripps Research, United States
    Pancreatic ductal adenocarcinoma requires PI3K? activity to accelerate circulating DNA-positive metastatic disease.
    Fernanda RAMOS-DELGADO, CRCT , France
    Targeting Mitochondrial Iron Metabolism Re-Sensitizes Resistant Acute Myeloid Leukemia Cells to Cytarabine
    Estelle SALAND, Inserm U1037, France
    A drug-tolerant senescent-like state promotes EGFR-TKI resistance and can be targeted with Rho/AKT inhibitors
    Sarah FIGAROL, Cancer Research Center of Toulouse, France
    A new role for cytidine deaminase in the control of DNA replication and genome stability in pancreatic cancer cells
    Audrey LUMEAU, CRCT-10, France
    Psychological and social impact of adapted physical activity (APA), namely touch rugby, in patients followed for gynecological and breast cancer
    Kelig VERGRIETE, Centre Hospitalier Universitaire , France
    PI3K? signaling controls the balance between tissue regeneration and precancer lesion formation via PHGDH expression in pancreatic inflammation.
    Coralie CAYRON, CRCT, France
    Evaluating PRL2 as a new target for glioblastoma treatment
    Tiffanie CHOULEUR, INSERM U1029 - Université de Bordeaux, France
    Molecular profiling of Midostaurin-resistant leukemic cells using CRISPR-Cas9 screening
    Solène FERNANDEZ, U1035 BMGIC- Université de Bordeaux, France
    RIP140 participates in the transcriptional interplay between p53 and HIF-2alpha to regulate glucose metabolism in cancer cells
    Catherine TEYSSIER, Institut de Recherche en Cancérologie de Montpellier, France
    Microtubule associated proteins as predictive biomarkers of taxane-based chemotherapy in high-grade serous ovarian cancer
    Hadia MOINDJIE, Institut Gustave Roussy, France
    Cancer cells replication program flexibility in response to replication stress
    Lilas COURTOT, CRCT INSERM 1037, France
    Long Noncoding RNAs in NPM1-mutated cytogenetically normal acute myeloid leukemia: clinical relevance and functional characterization
    Morgane GOURVEST, Centre de Recherches en Cancérologie de Toulouse - CRCT, France
    Ceramide metabolism alterations in TNF-induced resistance to immune checkpoint blockers in melanoma
    Carine DUFAU, CRCT Inserm 1037, France
    A new role of CEBPA in Acute Myeloid Leukemia : from differentiation to lipid and mitochondrial metabolism
    Marie SABATIER, CRCT - Inserm UMR1037, France
    Tumor adaptation of oncolytic virus to overcome pancreatic cancer resistance to treatment
    Pierre CORDELIER, INSERM U1037 équipe 10, France
    Towards precision Medicine: How bladder PDX models can support therapeutic decisions
    Yolande MISSERI, Urosphere, France
    Free-5S particles as new anti-cancer therapeutic target
    Simon LEBARON, CBI-INSERM, France
    Camilia MACHOU, University of Paris Est / INSERM U955, France
    The POLE cohort: Multicentric prospective cohort of tumors with somatic mutation of the DNA polymerase PolE, from bed side to bench !
    Nadim FARES, Cancer Research Center of Toulouse - CRCT, France
    Feasibility of circulating tumour DNA quantification in early breast cancer
    Hadrien Reboul, Caldas lab - Cancer Research UK Cambridge Institute, University of Cambridge, United Kingdom
    Integrated analysis of H2A.Z isoforms function reveals a complex interplay in gene regulation
    Assala LAMAA, CBI Toulouse, CNRS, France
    NELF-mediated RNA polymerase II pausing protects genes from DSBs by facilitating the loading of Set2/Hypb H3K36 methyltransferase
    David DEPIERRE, CBI-LBME, France
    Resistance of Melanoma to Immune Checkpoint Inhibitors is Overcome by Targeting the Sphingosine Kinase 1
    Céline COLACIOS, CRCT, France
    Autophagy, a new potential therapeutic target in JAK2V617F positive Myeloproliferative Neoplasms
    Charly COURDY, Centre de Recherches en Cancérologie de Toulouse (CRCT), France
    Polymorphism of Heat Shock Protein 70 (HSP70-2) and bladder cancer in an Algerian population
    Meriem BELHOUT ZEBIRI, University of Sciences and Technology Houari Boumediene, Algeria
    First-in-class imaging approach for single-cell, real-time analysis of oncolytic virus replication and efficacy in cancer cells
    Lorraine QUILLIEN, Cancer Research Centre of Toulouse (CRCT), UMR INSERM 1037, Toulouse, France, France
    Selective RhoC-dependent killing of cancer cells with mesenchymal phenotype: a new determinant for parvovirus minute virus of mice oncolytic activity in PDAC
    Pierre CORDELIER, Cancer Research Center of Toulouse (CRCT), UMR INSERM U1037 Team 10, Toulouse, France, France
    Mechanical parameter assessment of pancreatic cancer with Magnetic Resonance Elastography
    A better understanding of the E3 ubiquitin ligase TRIP12 heterogeneity to better treat pancreatic cancer
    Manon BRUNET, Inserm U1037-CRCT, France
    Role of CD36 in the response to chemotherapy in Acute Myeloid Leukemia
    Thomas FARGE, INSERM, France
    DeltaNp63 expression in HPV-related head and neck cancers impacts patients' prognosis, cancer cell aggressiveness and the intra-tumoral immune landscape
    Alain JUNG, Centre de lutte contre le cancer Paul Strauss, France
    A catalytic-independent function of the human DNA polymerase Kappa controls the pool of the checkpoint kinase Chk1
    Marie-Jeanne PILLAIRE, INSERM - CRCT, France
    The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities
    Melissa ALAME, Institut de Recherche en Cancérologie de Montpellier, France
    Conception, Preclinical and clinical validations of "Imdendrim", a new anti-cancer agent derived from the nanotechnology
    MET exon 14 skipping mutations in lung cancer: Screening, functional and clinical impact
    David TULASNE, CNRS UMR8161, France
    The T cell bispecific antibody CD20-TCB shows high in vitro activity against in vivo ibrutinib-treated primary CLL samples
    Anne QUILLET-MARY, CRCT, France
    Bifunctional ligand design for modulating mutant P53 aggregation in cancer
    Christian GAIDDON, INSERM U1113, France
    Extracellular matrix gene expression and cytotoxic T lymphocyte infiltration in the tumor microenvironment in non-small cell lung cancer
    Sara MILOSEVIC, Advanced Cell Diagnostics, a Bio-Techne Brand, France
    JMJD6 participates in the maintenance of ribosomal DNA integrity in response to DNA damage
    Innovative technical platform in radiochemistry and radiopharmacy (Pi-R2)
    Manon PEREZ, Toulouse Neuro Imaging Center (ToNIC) UMR1214 Inserm/UPS, France
    Targeting sphingosine-metabolizing enzymes: a novel strategy to bypass immune resistance in experimental melanoma
    Alexandre GHENASSIA, INSERM UMR 1037 CRCT, France
    Genetic variations of ABC transporters and CYP450 associated with Trabectedin hepatotoxicity in patients with advanced soft-tissue sarcomas: a pharmacogenetic study.
    Maud MAILLARD, Team 14 CRCT INSERM UMR1037, France
    HDAC4 levels control sensibility toward cisplatin in gastric cancer via p53/p73/BIK pathway
    Georg MELLITZER, INSERM UMR_S1113, France
    Modeling Cancer Initiation
    Adouda ADJIRI, University FA Setif-1 Faculty of Sciences , Algeria
    KDM5 histone-demethylases contribute to replication stress response and tolerance
    Senescence as an adaptive, oncogenic mechanism
    Olivier COQUERET, Inserm U1232, ICO Paul Papin, France
    Using DNA methylation to characterize cell types in the tumour microenvironment
    Ting XIE, Inserm Centre de Recherches en Cancerologie de Toulouse, France
    The adipose tissue that surrounds the prostate gland exhibits traits of hypoxic state that could contribute to its role in prostate cancer progression
    David ESTEVE, Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, Toulouse, France, France
    Investigating pluripotency, differentiation, cancer and resistance using network representations of the genome
    Vera PANCALDI, Inserm Centre de Recherches en Cancerologie de Toulouse, France
    Concomitant targeting of calcium mitochondrial homeostasis and autophagy: a new strategy to increase chemosensitivity of solid cancers.
    Charlotte DUBOIS, INSERM, France
    Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth
    Jean Philippe HUGNOT, Université de Montpellier, France
    Development of an TAM targeting antibody for cancer therapy
    Marcin DOMAGALA, Cancer Research Center of Toulouse, France
    CD137 receptor as a candidate for therapeutic induction of high endothelial venules in solid tumors
    Lucas BLANCHARD, Institut de Pharmacologie et de Biologie Structurale, France
    Microtubule-associated ATIP3 deficiency sensitizes breast tumors to paclitaxel by increasing aneuploidy
    Sylvie RODRIGUES-FERREIRA, Institut Gustave Roussy, France
    Multiscale modelling of macrophage polarization in Chronic Lymphocytic Leukemia
    Nina VERSTRAETE, Cancer Research Center of Toulouse UMR 1037 Inserm - Université Toulouse III Paul Sabatier, France
    Tumor growth, progression and immune escape are modulated by ATRX alterations in pleomorphic sarcomas
    Lucie DARMUSEY, CRCT, France
    The Study of Synergistic and Protective Effects of Three Different Polar Saffron Extracts and Photon Radiation on Human Colorectal Cancer Cells (Ht-29) and Normal Human
    Roham SALEK, mashhad univercity of medical scienses , Iran
    Detection of BRAF V600E mutation by immunohistochemistry and PCR- RFLP in Moroccan patients with Pediatric Low-Grade Gliomas
    Soufiane HENNANI, Laboratory of Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II - Casablanca, Morocco , Morocco
    Phosphoantigenic activation of Vg9Vd2 T lymphocytes: involvement of RHOB in a lung cancer model
    Chloé LAPLAGNE, Cancer Research Center of Toulouse - CRCT , France
    PRIMAGE: PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers
    Thomas TROUILLARD, Medexprim, France
    The histone variant macroH2A1.1 inhibits cellular migration by activating paused gene transcription in triple negative breast cancer cells.
    Ludmila RECOULES, CBI, France
    LungPredict: Transcriptomics and imaging to explore the lung cancer tumor microenvironment landscape, a multidisciplinary approach to personalized medicine
    Vera PANCALDI, Cancer Research Center of Toulouse (CRCT), France

    Preliminary programme up to date 30 Jan. 2020